Medical Digest & Congress Report

Kate Lathrop, MD discuss one of the high impact, clinically relevant, clinical trial, the lidERA trial that were presented at the San Antonio Breast Cancer Symposium 2025.

Video: https://medicaldigest.org/scientific-contents/interview:program-directors-choice-sabcs2025-part-1-giredestrant-improves-disease-free-survival-patients-early-stage-breast-cancer-phase-iii-lidera-trial

Prof. Virginia G. Kaklamani discuss some of the high impact, clinically relevant, clinical trials that were presented at the San Antonio Breast Cancer Symposium 2025, like the lidERA, HER2CLIMB-05 and WISDOM trial.

Video: https://medicaldigest.org/scientific-contents/interview:highligths-sabcs-2025

Matthew S. Davids discusses the available research guiding the selection of therapy for patients with chronic lymphocytic leukemia at the American Society of Hematology's 67th Annual Meeting.

Video: https://medicaldigest.org/scientific-contents/interview:available-research-guiding-selection-therapy-patients-chronic-lymphocytic-leukemia

Catherine S. Diefenbach discusses the lymphoma and CLL highlights at the American Society of Hematology's 67th Annual Meeting.

Video: https://medicaldigest.org/scientific-contents/interview:lymphoma-and-cll-highlights-ash-2025

Rahul Banerjee discusses the quadruplet therapy in multiple myeloma at the American Society of Hematology's 67th Annual Meeting.

Video: https://medicaldigest.org/scientific-contents/interview:quadruplet-therapy-multiple-myeloma

Jennifer Woyach discusses the noncovalent BTK inhibitor pirtobrutinib achieved noninferiority to the covalent BTK inhibitor ibrutinib in terms of overall response rate in patients with CLL or SLL, according to findings from a randomized phase III trial presented at the American Society of Hematology's 67th Annual Meeting.

Video: https://medicaldigest.org/scientific-contents/interview:non-covalent-btki-pirtobrutinib-shows-promise-frontline-therapy-cllsll

Anand A. Patel discusses the primary efficacy analysis of a Phase II study investigating tyrosine kinase inhibitor and inotuzumab ozogamicin-based therapy for newly diagnosed Philadelphia-chromosome-positive acute lymphoblastic leukemia at the American Society of Hematology's 67th Annual Meeting.

Video: https://medicaldigest.org/scientific-contents/interview:primary-efficacy-analysis-tki-and-inotuzumab-ozogamicin-based-therapy-newly-diagnosed-ph-all

Jesse Tettero discusses the results from the HARMONY Alliance study at the American Society of Hematology's 67th Annual Meeting.

Video: https://medicaldigest.org/scientific-contents/interview:validation-measurable-residual-disease-surrogate-endpoint-acute-myeloid-leukemia-harmony-alliance-study-european-randomized-trials

Jennifer R. Brown explains the results from the ALPINE trial at the American Society of Hematology's 67th Annual Meeting.

Video: https://medicaldigest.org/scientific-contents/interview:symptom-based-progression-free-survival-clinically-relevant-and-patient-centric-endpoint-chronic-lymphocytic-leukemiasmall-lymphocytic-lymphoma-results-alpine-trial

Amir Fathi discusses the results from a phase 2 randomized multi-center study comparing azacitidine and venetoclax to conventional induction chemotherapy for newly diagnosed fit adults with acute myeloid leukemia at the American Society of Hematology's 67th Annual Meeting.

Video: https://medicaldigest.org/scientific-contents/interview:azacitidinevenetoclax-combination-outperforms-standard-care-acute-myeloid-leukemia-patients-eligible-intensive-chemotherapy